These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17300834)

  • 21. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccinia virus and oncolytic virotherapy of cancer.
    Thorne SH; Hwang TH; Kirn DH
    Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
    Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
    Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
    Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
    Dorer DE; Nettelbeck DM
    Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic viral therapies - the clinical experience.
    Aghi M; Martuza RL
    Oncogene; 2005 Nov; 24(52):7802-16. PubMed ID: 16299539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.
    Zhang H; Takayama K; Zhang L; Uchino J; Harada A; Harada T; Hisasue J; Nakagaki N; Zhou C; Nakanishi Y
    Cancer Gene Ther; 2009 May; 16(5):415-22. PubMed ID: 19148207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
    Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
    Liu TC; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicellular tumor spheroids in gene therapy and oncolytic virus therapy.
    Lamfers ML; Hemminki A
    Curr Opin Mol Ther; 2004 Aug; 6(4):403-11. PubMed ID: 15468599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond.
    Kaufmann JK; Nettelbeck DM
    Trends Mol Med; 2012 Jul; 18(7):365-76. PubMed ID: 22633438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses.
    Working PK; Lin A; Borellini F
    Oncogene; 2005 Nov; 24(52):7792-801. PubMed ID: 16299538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
    Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
    Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction: gene therapy of cancer.
    Lattime EC; Gerson S
    Semin Oncol; 2005 Dec; 32(6):535-6. PubMed ID: 16338418
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.
    Liu TC; Galanis E; Kirn D
    Nat Clin Pract Oncol; 2007 Feb; 4(2):101-17. PubMed ID: 17259931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.